Skip to content

Trivalent Chromium Treatment for Rheumatoid Arthritis

Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05545020
Enrollment
60
Registered
2022-09-19
Start date
2022-12-25
Completion date
2024-01-13
Last updated
2024-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

Trivalent chromium has shown good results in abolishing inflammation and had a successful result in treating animal model of rheumatoid arthritis. In addition to that, trivalent chromium lacks many side effects which are related to the already known medications of the disease. So this study aims to evaluate the efficacy of trivalent chromium supplementation in rheumatoid arthritis treatment and measuring the outcomes of that in rheumatoid arthritis patients.

Detailed description

Rheumatoid arthritis is a debilitating autoimmune disease which is treated by medications that have many side effects. Trivalent chromium, a naturally occurring element with regulatory effects on blood sugar, has shown anti-inflammatory properties in many studies and has shown a good response at alleviation of rheumatoid arthritis in the disease animal model. For these reasons trivalent chromium should be tried in rheumatoid arthritis patients.

Interventions

DRUGTrivalent chromium versus synthetic and/ or biological DMARDs

Supplement and immunesuppressants

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* rheumatoid arthritis

Exclusion criteria

* other autoimmune diseases

Design outcomes

Primary

MeasureTime frameDescription
Radiological investigations if required (X-RAY, ultrasound, MRI, bone scan)three monthsTo assess joints and bone
Arthritis scored by DAS28 scorethree monthsDAS 28 is a score of arthritis
ESR in mm/hrthree monthslab measures for disease activity
CRP mg/dLthree monthslab measures for disease activity

Secondary

MeasureTime frameDescription
Serum ureathree monthsA renal function test to exclude trivalent chromium side effects.
serum creatininethree monthsA renal function test to exclude trivalent chromium side effects.
SGOTthree monthsA liver function test to exclude trivalent chromium side effects.
SGPTthree monthsA liver function test to exclude trivalent chromium side effects.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026